Ernexa Therapeutics Inc (ERNA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 09-2025 | 06-2025 | 03-2025 | 12-2024 | 09-2024 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -12,582 | -11,341 | -8,202 | -44,539 | -38,780 |
| Depreciation Amortization | 194 | 124 | 69 | 6,897 | 3,718 |
| Accounts receivable | 284 | 283 | 281 | -12 | 238 |
| Other Working Capital | 21 | -258 | 226 | -1,801 | -107 |
| Other Operating Activity | 6,214 | 6,595 | 5,561 | 23,619 | 22,640 |
| Operating Cash Flow | $-5,869 | $-4,597 | $-2,065 | $-15,836 | $-12,291 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -22 | N/A | N/A | -365 | -365 |
| Investing Cash Flow | $-22 | $N/A | $N/A | $-365 | $-365 |
| Cash Flows From Financing Activities | |||||
| Debt Issued | 2,250 | 2,250 | 2,250 | 5,292 | 3,887 |
| Common Stock Issued | 4,959 | 4,933 | 4 | 1,137 | N/A |
| Dividend Paid | N/A | N/A | N/A | N/A | -8 |
| Other Financing Activity | 0 | 0 | 0 | -169 | 1,371 |
| Financing Cash Flow | $7,209 | $7,183 | $2,254 | $6,260 | $5,250 |
| Beginning Cash Position | 1,729 | 1,729 | 1,729 | 11,670 | 11,670 |
| End Cash Position | 3,047 | 4,315 | 1,918 | 1,729 | 4,264 |
| Net Cash Flow | $1,318 | $2,586 | $189 | $-9,941 | $-7,406 |
| Free Cash Flow | |||||
| Operating Cash Flow | -5,869 | -4,597 | -2,065 | -15,836 | -12,291 |
| Capital Expenditure | -22 | N/A | N/A | -369 | -369 |
| Free Cash Flow | -5,891 | -4,597 | -2,065 | -16,205 | -12,660 |